Effects of everolimus (Certican) on cardiac hypertrophy and carotid atherosclerosis after kidney transplantatio

Phase 4

Recruiting

• Conditions: Ventricular hypertrophy and carotid atherosclerosis; C14.280.195.400; C10.228.140.300.200

• Registration Number: RBR-26qdtg
• Lead Sponsor: Hospital das Clínicas da Faculdade de Medicina de Botucatu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-01-16
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

The patient who agree to participate in the study, who have a consent form signed and meet the following criteria: age of 30 years or greater and being a recipient of de novo kidney transplant from a deceased donor or non-HLA identical living donor. At randomization time the patients needs to meet this criteria: creatinine clearance estimated by Cockroft-Gault formula of 40ml/min or greater and proteinuria of 800mg/day or less.

Exclusion Criteria

Patients will be excluded of the study if: with painel reactive antibody of 50% or higher, recipients of a second transplant with the first transplant loss for any immunological cause within the first year of transplantation, multi-organ recipient, ABO incompatible donor; non-beating heart donor; donor age of 5 yars or less and donor age of 65 years or higher. At the randomization time, patients will be excluded if: they were on a rejection treatment, if they have history of Baff IIB or higher rejection insult, previous rejection resistant to corticosteroids, presence of subclinical rejection or severe inflammation on protocolar biopsy, presence of total blood cont leucocyte of 2500uL or less, neutrofiles of 1500uL or less, platelets of 75000uL or less, hemoglobin of 6,0g/L or less, liver disease or active infection, positive pregnancy test

Study & Design

• Study Type: Intervention
• Study Design: Not specified